Future Plans

AGT's commercial strategy is to develop collaborative research prospects and alliances for product development. This partnership will bring about syn­er­gism and "win-win" outcomes addressing complexities in AD health care. At present, AGT does not intend to become a fully integrated global pharmaceutical company, supporting its own inde­pendent sales, manufacturing and marketing forces. Rather, AGT's business strategy is to be­come a discovery and early development evaluation company, focusing on microRNAs as bio­marker discovery for diagnosis and therapeutic treatment of Alzheimer's disease and MCI. Our database of microRNAs and their target proteins in circulating plasma, and other knowledge-based dis­co­v­ery of similar key molecules, should provide an attractive position for AGT's collab­orative ap­proach to partner with globally oriented pharmaceutical companies in AD health care. AGT's business model is mainly to form alliances with strategic partners of two different types; the first is to perform contract service-oriented R&D for other companies, while pursuing govern­ment grant-supported technology development towards AD diagnosis. This will support us to seek the second type of partnership, i.e. dealing with established large pharmaceutical companies cap­able of developing our tests of expression levels of circulating plasma microRNAs and their tar­get proteins into AD technology products for the marketplace. The AD plasma RNA diag­nos­tic will be the first such deal to be negotiated, thus providing the revenue stream to con­tinue re­search and development of other pipeline products planned for AGT's Tool Box. The end result will be a valuable and competitive global AD-directed product portfolio, which should con­tinue to be at­tractive to large AD pharmaceutical companies for strategic alliances.